By Maria V. Gallagher, Legislative Director, Pennsylvania Pro-Life Federation
This week’s U.S. Supreme Court ruling upholding the FDA requirement that banned the mailed distribution of abortion drugs is already having a positive impact on Pennsylvania.
Planned Parenthood Keystone has removed from its website a page touting abortions by mail. The abortion giant openly avowed that abortions by mail were designed to expand abortion in the Keystone State.
But with the Supreme Court’s FDA v. American College of Obstetricians and Gynecologists decision, Planned Parenthood has obviously been forced to rethink its latest abortion marketing ploy.
RU486 abortions/chemical abortions [called by proponents “medication abortions”) have been on the rise in the Commonwealth of Pennsylvania. From 2018 to 2019, the number of chemical abortions increased from 12,466 to 13,845. This increase contributed to the slightly more than 2% increase in abortion totals statewide.
At the same time, complications from abortions have risen dramatically in Pennsylvania. In 2019, according to figures from the PA Department of Health, 285 complications from abortion were reported, an astronomical increase of more than 59% over the 2018 totals. The vast majority of the complications—82%—involved baby body parts being left behind in mothers’ wombs. Other complications included excessive bleeding and infection.
Chemical abortions are especially traumatic because they leave women to deal with the aftermath of abortion on their own, in their own homes, without a physician present. Each time they return to the bathroom, they may be reminded of the trauma of losing their child to abortion. In this way, chemical abortions can pose serious emotional health risks for mothers.
The High Court should be applauded for placing a priority on sound medical concerns, rather than appeasing the abortion industry, which appears far more interested in making money than safeguarding women’s health.